No Data
No Data
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript
Earnings Call Summary | Relmada Therapeutics(RLMD.US) Q1 2024 Earnings Conference
The following is a summary of the Relmada Therapeutics, Inc. (RLMD) Q1 2024 Earnings Call Transcript:Financial Performance:Relmada Therapeutics reported a decrease in total research and development ex
Buy Rating for Relmada Therapeutics Supported by Strong Clinical Pipeline and Financial Stability
Relmada Therapeutics Inc (RLMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Relmada Therapeutics Q1 2024 GAAP EPS $(0.72) Beats $(0.84) Estimate
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.84) by 14.29 percent. This is a 17.24 percent increase over losses of
Relmada Therapeutics | 10-Q: Quarterly report